Articles related to SKIN CANCER

PORT is recommended for patients with cSCC having close or positive margins that cannot be corrected with further surgery (secondary to morbidity or adverse cosmetic outcome). In patients with cSCC, PORT is recommended for T3 and T4 tumors—both strong recommendations with moderate to low evidence quality.

“These results would really shift our practice from starting it once patients have developed numerous skin cancers to starting it earlier. We still need to do a better job of identifying who will actually benefit, as roughly only half of patients will develop multiple skin cancers.” – Lee Wheless, MD, PhD

Basal cell carcinoma, while common, rarely leads to death when detected and treated early. Physicians should be aware of the seven warning signs that can be mistaken for harmless skin conditions.

The integration of AI in skin cancer diagnostics not only improves the accuracy of diagnoses—achieving a sensitivity of 81.1% and specificity of 86.1%—but also supports the broader application of AI tools in enhancing patient care across various medical specialties.

Amtagvi’s approval introduces a novel approach in the treatment of advanced melanoma, employing patient-derived TIL-cell therapy to target tumors with precision, offering a beacon of hope for those with limited options.

Equip yourself with comprehensive knowledge about skin cancer to better educate your patients. Learn more about its types, symptoms, risk factors, diagnosis methods, treatments, stages, complications, and prevention strategies.